{"url_path":"/sec/ptix/8-k/2026-02-24/item-2-01","section_key":"item-2-01","section_title":"Item 2.01 Completion of Acquisition or Disposition of Assets**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-24","source_url":"https://www.sec.gov/Archives/edgar/data/1022899/0001493152-26-007800-index.html","accession_number":"0001493152-26-007800","cik":"0001022899","ticker":"PTIX","issuer_name":"Protagenic Therapeutics, Inc.\\new","edgar_url":"https://www.sec.gov/Archives/edgar/data/1022899/0001493152-26-007800-index.html","primary_entity_key":"0001022899","primary_entity_name":"Protagenic Therapeutics, Inc.\\new"},"word_count":66,"has_tables":true,"body_markdown":"**Item\n2.01 Completion of Acquisition or Disposition of Assets**\n\n \n\nOn\nFebruary 17, 2026, pursuant to the Unwind Agreement, PTIX disposed of its ownership interest in Phytanix Bio and returned 100% of the\nissued and outstanding shares of Phytanix Bio to the Former Phytanix Stockholders. In exchange, PTIX received for cancellation all shares\nof PTIX common stock and preferred stock previously issued as consideration under the SEA."}